Other Transaction Agreement HT94252590011
Award Date
5/5/25
Potential Completion Date
5/4/28
Potential Value
$30M
Federal Agency
Defense Health Agency
Awardee
Ophirex, Inc.
Ultimate Awardee
Not listed
NAICS Category
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed
Major Defense Program
Not listed
Pricing Type
Other
Place of Performance
Corte Madera, CA 94925, USA
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $9,407,618.00 firm fixed price definitive contract awarded by the Defense Health Agency to Ophirex, Inc., a small business, for the development of a broad-spectrum snakebite antidote. The contract is part of the U.S. Army Medical Research and Development Command's Small Business Innovation Research (SBIR) Phase III program, which provides for the continued research and development of technologies that have successfully completed Phases I and II. The contract aims to advance the...
This is a Small Business Innovation Research (SBIR) Phase II medical research and development contract awarded by the Defense Health Agency (DHA) to Ophirex, Inc., a small business located in Corte Madera, California. The contract, valued at $1,525,194.76, is for the development of a "Broad Spectrum Envenomation Treatment" to address snakebite injuries. The contract has a firm fixed price and a total small business set aside designation. This contract builds upon previous SBIR Phase...
This is a firm fixed price, definitive contract awarded by the Department of the Army Medical Command to Ophirex, Inc., a small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $148,509.12, is for the development of a broad-spectrum envenomation treatment. Ophirex, a for-profit organization, has previously received SBIR Phase II and III awards from the Department of the Army Medical Command and the Defense Health Agency for related research...
Ophirex, Inc. has been awarded a firm fixed price definitive contract valued at $1,299,779 by the Department of the Army Medical Command. This contract is a Small Business Innovation Research Program Phase II award to further develop Ophirex's intravenous snakebite antidote varespladib. Specifically, the contract aims to improve recovery time following snakebite through metalloprotease inhibition. As a total small business set aside, this award will support Ophirex's continued medical research...
This is a firm-fixed price definitive contract awarded by the Department of the Army Medical Command to CRO LLC, a small disadvantaged veteran-owned limited liability company, to provide one shipment of polyvalent F(ab')2 immunoglobulin fragments (equine), snake antivenom for multiple African nations. The contract has a total potential value of $151,200.00 and a completion date of October 17, 2022. The original solicitation was issued as a sole source special notice under the simplified...
The Department of the Army Medical Command awarded Ophirex, Inc. a $10.6 million definitive contract to support research and development efforts for a COVID-19 treatment under the Small Business Innovation Research Program Phase III. The prime contractor will conduct work at its place of performance in Corte Madera, California from June 2020 through September 2023 under the firm fixed price contract, which has a total small business set aside designation. Specifically, Ophirex will perform...
This is a $1,099,999.92 Firm Fixed Price SBIR Phase II contract awarded by the Joint PEO Chemical and Biological Defense, a component of the U.S. Army, to Consegna Pharma Inc., a small disadvantaged business. The contract is for the development of a long-duration opioid overdose antagonist. This award follows a prior $167,421 SBIR Phase I contract Consegna received from the Army for additional pharmaceutical research and development. Consegna has also received several grants from the National...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This federal contract award is a Blanket Purchase Agreement (BPA) call against the General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs, awarded to Rare Disease Therapeutics, Inc., a woman-owned small business. The contract, valued at $17,278, is for the provision of ANASCORP scorpion antivenom injections to the Indian Health Service (IHS), a civilian agency within the Department of Health and Human Services. The contract has an ultimate completion date of April 14,...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...